Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2015

01-07-2015 | Breast Oncology

Growing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States

Authors: Charles E. Rutter, MD, Henry S. Park, MD, MPH, Brigid K. Killelea, MD, MPH, Suzanne B. Evans, MD, MPH

Published in: Annals of Surgical Oncology | Issue 7/2015

Login to get access

Abstract

Background

Ductal carcinoma-in situ (DCIS) is a preinvasive form of breast cancer associated with excellent outcomes after either mastectomy or breast conservation therapy. Previous studies have demonstrated declining rates of mastectomy. However, it is unclear how this pattern has changed in recent years.

Methods

Women with DCIS were identified within the National Cancer Data Base. Patients treated with lumpectomy with or without radiotherapy were compared to women treated with mastectomy on the basis of demographic, clinicopathologic, and reporting facility details using χ 2 tests and multivariable logistic regression modeling to identify factors that may influence surgical choice. Changes in the proportion of women receiving contralateral prophylactic mastectomy (CPM) were assessed in a similar fashion.

Results

We identified 212,936 women diagnosed with DCIS between 1998 and 2011. Lumpectomy was performed in 68 % (144,681) of patients. Mastectomy rates initially declined from 1998 (36 %) through 2004 (28 %), before increasing again through 2011 (33 %). Younger patient age, greater medical comorbidity, more extensive disease, higher tumor grade, treatment at an academic facility, and greater distance from the reporting facility were associated with heightened use of mastectomy (all p < 0.001). CPM also increased over time, particularly among younger patients, on multivariate analysis (p < 0.001).

Conclusions

Mastectomy utilization appears to be rising between 2004 and 2011, particularly among younger patients and those with higher-risk histopathologic features. CPM is increasing in a similar fashion. Further research is needed to understand the drivers of this change.
Literature
1.
Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913–8.PubMedCrossRef
2.
Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 2005;103:1778–84.PubMedCrossRef
3.
Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. BMJ. 2006;332(7543):727.PubMedCentralPubMedCrossRef
4.
Eusebi V, Foschini MP, Cook MG, Berrino F, Azzopardi JG. Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Semin Diagn Pathol. 1989;6:165–73.PubMed
5.
Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer. 1995;76:1197–200.PubMedCrossRef
6.
Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997;127:1023–8.PubMedCrossRef
7.
8.
Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103:478–88.PubMedCentralPubMedCrossRef
9.
EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.CrossRef
10.
Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26:1247–52.PubMedCrossRef
11.
Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102.PubMedCrossRef
12.
Zujewski JA, Harlan LC, Morrell DM, Stevens JL. Ductal carcinoma in situ: trends in treatment over time in the US. Breast Cancer Res Treat. 2011;127:251–7.PubMedCrossRef
13.
Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–8.PubMedCrossRef
14.
Punglia RS, Schnitt SJ, Weeks JC. Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate? J Natl Cancer Inst. 2013;105:1527–33.PubMedCrossRef
15.
Evans D, Barwell J, Eccles D, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16:1–6.CrossRef
16.
17.
Rutter CE, Chagpar AB, Evans SB. Breast cancer laterality does not influence survival in a large modern cohort: implications for radiation-related cardiac mortality. Int J Radiat Oncol Biol Phys. 2014;90:329–34.PubMedCrossRef
18.
Piot-Ziegler C, Sassi ML, Raffoul W, Delaloye JF. Mastectomy, body deconstruction, and impact on identity: a qualitative study. Br J Health Psychol. 2010;15(Pt 3):479–510.PubMedCrossRef
19.
Polsky D, Mandelblatt JS, Weeks JC, et al. Economic evaluation of breast cancer treatment: considering the value of patient choice. J Clin Oncol. 2003;21:1139–46.PubMedCrossRef
20.
Palit TK, Miltenburg DM, Brunicardi FC. Cost analysis of breast conservation surgery compared with modified radical mastectomy with and without reconstruction. Am J Surg. 2000;179:441–5.PubMedCrossRef
21.
Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6:546–52.PubMedCrossRef
22.
Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004;101:1977–86.
23.
McGuire KP, Santillan AA, Kaur P, et al. Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16:2682–90.PubMedCrossRef
24.
Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13:349–55.PubMedCentralPubMedCrossRef
25.
Elsayegh N, Kuerer HM, Lin H, et al. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014;21:3466–72.PubMedCrossRef
26.
Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–7.PubMedCrossRef
27.
Sue GR, Lannin DR, Au AF, Narayan D, Chagpar AB. Factors associated with decision to pursue mastectomy and breast reconstruction for treatment of ductal carcinoma in situ of the breast. Am J Surg. 2013;206:682–5.PubMedCrossRef
28.
Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer. 2009;100:1048–54.PubMedCentralPubMedCrossRef
29.
Driul L, Bernardi S, Bertozzi S, Schiavon M, Londero AP, Petri R. New surgical trends in breast cancer treatment: conservative interventions and oncoplastic breast surgery. Minerva Ginecol. 2013;65:289–96.PubMed
30.
El-Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg. 2007;245:665–71.PubMedCentralPubMedCrossRef
31.
Taghian A, de Vathaire F, Terrier P, et al. Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys. 1991;21:361–7.PubMedCrossRef
32.
Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23:7475–82.PubMedCrossRef
33.
34.
Covelli AM, Baxter NN, Fitch M, Wright FC. Examining health beliefs: why mastectomies are on the rise. Paper presented at 2014 ASCO Quality Care Symposium.
Metadata
Title
Growing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States
Authors
Charles E. Rutter, MD
Henry S. Park, MD, MPH
Brigid K. Killelea, MD, MPH
Suzanne B. Evans, MD, MPH
Publication date
01-07-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 7/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4334-x

Other articles of this Issue 7/2015

Annals of Surgical Oncology 7/2015 Go to the issue

Gastrointestinal Oncology

The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience

Bone and Soft Tissue Sarcomas

Predictive Ability of Blood Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Gastrointestinal Stromal Tumors

Gastrointestinal Oncology

Laparoscopic Suprapancreatic Lymph Node Dissection for Advanced Gastric Cancer Using a Left-Sided Approach

Pancreatic Tumors

Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma

Colorectal Cancer

Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?

Endocrine Tumors

Improving Outcomes in Adrenocortical Cancer: An Australian Perspective